RS55874B1 - Indoli - Google Patents
IndoliInfo
- Publication number
- RS55874B1 RS55874B1 RS20170410A RSP20170410A RS55874B1 RS 55874 B1 RS55874 B1 RS 55874B1 RS 20170410 A RS20170410 A RS 20170410A RS P20170410 A RSP20170410 A RS P20170410A RS 55874 B1 RS55874 B1 RS 55874B1
- Authority
- RS
- Serbia
- Prior art keywords
- indoles
- Prior art date
Links
- 150000002475 indoles Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33230910P | 2010-05-07 | 2010-05-07 | |
EP11778334.0A EP2566327B1 (en) | 2010-05-07 | 2011-05-05 | Indoles |
PCT/US2011/035336 WO2011140324A1 (en) | 2010-05-07 | 2011-05-05 | Indoles |
Publications (1)
Publication Number | Publication Date |
---|---|
RS55874B1 true RS55874B1 (sr) | 2017-08-31 |
Family
ID=44904072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20170410A RS55874B1 (sr) | 2010-05-07 | 2011-05-05 | Indoli |
Country Status (33)
Country | Link |
---|---|
US (5) | US8536179B2 (sr) |
EP (2) | EP2566327B1 (sr) |
JP (1) | JP5864545B2 (sr) |
KR (1) | KR20130062290A (sr) |
CN (1) | CN102970869B (sr) |
AU (1) | AU2011248068B2 (sr) |
BR (1) | BR112012028556A2 (sr) |
CA (1) | CA2798622C (sr) |
CL (1) | CL2012003110A1 (sr) |
CR (1) | CR20120565A (sr) |
CY (1) | CY1119006T1 (sr) |
DK (1) | DK2566327T3 (sr) |
DO (1) | DOP2012000282A (sr) |
EA (1) | EA023788B1 (sr) |
ES (1) | ES2627085T3 (sr) |
HR (1) | HRP20170736T1 (sr) |
HU (1) | HUE034787T2 (sr) |
IL (1) | IL222878A (sr) |
LT (1) | LT2566327T (sr) |
MA (1) | MA34284B1 (sr) |
ME (1) | ME02757B (sr) |
MX (1) | MX2012012966A (sr) |
MY (1) | MY184101A (sr) |
NZ (1) | NZ603454A (sr) |
PE (1) | PE20130647A1 (sr) |
PL (1) | PL2566327T3 (sr) |
PT (1) | PT2566327T (sr) |
RS (1) | RS55874B1 (sr) |
SG (1) | SG185431A1 (sr) |
SI (1) | SI2566327T1 (sr) |
UA (1) | UA110112C2 (sr) |
WO (1) | WO2011140324A1 (sr) |
ZA (1) | ZA201208447B (sr) |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5864546B2 (ja) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | インダゾール |
CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
US8895245B2 (en) | 2010-09-10 | 2014-11-25 | Epizyme, Inc. | Inhibitors of human EZH2 and methods of use thereof |
EP2646020B1 (en) * | 2010-12-01 | 2016-09-21 | Glaxosmithkline LLC | Indoles |
AU2012223448B2 (en) * | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
AU2013203641B2 (en) * | 2011-04-13 | 2014-08-21 | Epizyme, Inc. | Aryl-or heteroaryl-substituted benzene compounds |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
AU2012332297B2 (en) * | 2011-11-04 | 2016-01-07 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
WO2013075083A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CA2857344C (en) | 2011-12-21 | 2019-02-12 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
EP2812001B1 (en) * | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
ES2718900T3 (es) | 2012-03-12 | 2019-07-05 | Epizyme Inc | Inhibidores de EZH2 humana y métodos de uso de los mismos |
EP2828250B1 (en) | 2012-03-19 | 2021-03-10 | Imperial College Innovations Limited | Quinazoline compounds and their use in therapy |
EP2836491B1 (en) * | 2012-04-13 | 2016-12-07 | Epizyme, Inc. | Salt form of a human histone methyltransferase ezh2 inhibitor |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
CA2876304C (en) | 2012-06-14 | 2021-07-20 | Whitehead Institute For Biomedical Research | Genome-wide method of assessing interactions between chemical entities and their target molecules |
JP6505013B2 (ja) | 2012-08-28 | 2019-04-24 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 |
JP6254169B2 (ja) * | 2012-09-28 | 2017-12-27 | ファイザー・インク | ベンズアミドおよびヘテロベンズアミド化合物 |
WO2014062732A1 (en) | 2012-10-15 | 2014-04-24 | Epizyme, Inc. | Substituted benzene compounds |
KR20190105669A (ko) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
JP2016503009A (ja) | 2012-12-13 | 2016-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | Zesteホモログ2エンハンサー阻害剤 |
EP2934531A4 (en) * | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
WO2014100665A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
TWI629273B (zh) * | 2013-02-11 | 2018-07-11 | 美商星宿藥物公司 | 甲基修飾酵素之調節劑、其組成物及用途 |
AU2014222641B2 (en) | 2013-02-28 | 2018-03-15 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
US9765035B2 (en) | 2013-03-14 | 2017-09-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
EP2970135B1 (en) | 2013-03-14 | 2018-07-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
HUE052926T2 (hu) | 2013-03-14 | 2021-05-28 | Epizyme Inc | Arginin metiltranszferáz inhibitorok és ezek alkalmazása |
JP2016514164A (ja) | 2013-03-14 | 2016-05-19 | エピザイム,インコーポレイティド | アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用 |
WO2014153208A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014153214A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
EP2970134B1 (en) | 2013-03-14 | 2018-02-28 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
JP2016516046A (ja) | 2013-03-14 | 2016-06-02 | ジェネンテック, インコーポレイテッド | がんの治療方法及びがん薬物耐性を阻止する方法 |
US9365527B2 (en) | 2013-03-14 | 2016-06-14 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2014155301A1 (en) * | 2013-03-26 | 2014-10-02 | Piramal Enterprises Limited | Substituted bicyclic compounds as inhibitors of ezh2 |
JP6419155B2 (ja) | 2013-04-03 | 2018-11-07 | ヤンセン・サイエンシズ・アイルランド・ユーシー | N−フェニル−カルボキサミド誘導体およびb型肝炎を治療するための医薬品としてのその使用 |
KR20160003115A (ko) * | 2013-04-30 | 2016-01-08 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
US10160743B2 (en) | 2013-05-17 | 2018-12-25 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
KR20160018594A (ko) * | 2013-06-06 | 2016-02-17 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
CA2917463A1 (en) | 2013-07-10 | 2015-01-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
LT3024819T (lt) | 2013-07-25 | 2018-06-11 | Janssen Sciences Ireland Uc | Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui |
US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
PT3057962T (pt) | 2013-10-16 | 2023-11-07 | Epizyme Inc | Forma de sal cloridrato para inibição de ezh2 |
WO2015059212A1 (en) | 2013-10-23 | 2015-04-30 | Janssen R&D Ireland | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
WO2015077194A1 (en) * | 2013-11-22 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
MX2016009449A (es) | 2014-02-05 | 2016-10-13 | Novira Therapeutics Inc | Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb). |
EP3102572B1 (en) | 2014-02-06 | 2018-10-24 | Janssen Sciences Ireland UC | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US20160340674A1 (en) * | 2014-02-10 | 2016-11-24 | University Of Rochester | Compositions and Methods to Inhibit EZH2 for the Treatment of Cardiovascular Diseases |
EP3111222A1 (en) | 2014-02-26 | 2017-01-04 | Glaxosmithkline Intellectual Property (No. 2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
WO2015143424A2 (en) * | 2014-03-21 | 2015-09-24 | Glaxosmithkline Intellectual Property (No. 2) Limited | Methods of treating cancer |
CN105037360B (zh) * | 2014-04-28 | 2016-08-17 | 四川大学 | 吡啶酮衍生物及其制备方法和用途 |
CN105017221B (zh) * | 2014-04-30 | 2019-05-28 | 中国医学科学院药物研究所 | 苯并咪唑衍生物及其制法和药物组合物与用途 |
GEP20186933B (en) | 2014-06-17 | 2018-12-10 | Pfizer | Substituted dihydroisoquinoline compounds |
WO2015200650A1 (en) * | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
BR112017008840A2 (pt) * | 2014-10-28 | 2017-12-19 | Glaxosmithkline Ip No 2 Ltd | intensificador de inibidores do homólogo 2 de zeste |
EP3214935A4 (en) | 2014-11-06 | 2018-08-29 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
WO2016102493A1 (en) * | 2014-12-22 | 2016-06-30 | Bayer Pharma Aktiengesellschaft | Imidazopyridine ezh2 inhibitors |
US9580437B2 (en) * | 2014-12-23 | 2017-02-28 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
WO2016101956A2 (en) | 2014-12-23 | 2016-06-30 | University Of Copenhagen | Treatment of cancer by inhibiting ezh2 activity |
JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びb型肝炎感染症の治療法 |
EP3283502A4 (en) | 2015-04-07 | 2019-04-03 | The General Hospital Corporation | METHODS FOR REACTIVATION OF GENES ON INACTIVE X CHROMOSOME |
EP3307713A4 (en) * | 2015-06-10 | 2019-01-23 | Epizyme, Inc. | EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
SG10201909199PA (en) | 2015-08-24 | 2019-11-28 | Epizyme Inc | Method for treating cancer |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
AU2016330964B2 (en) | 2015-09-29 | 2021-04-01 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
KR20180058829A (ko) | 2015-10-06 | 2018-06-01 | 에피자임, 인코포레이티드 | Ezh2 억제제로 수모세포종을 치료하는 방법 |
WO2017079738A1 (en) | 2015-11-05 | 2017-05-11 | Epizyme, Inc. | Flow cytometry for monitoring histone h3 methylation status |
PT3378859T (pt) * | 2015-11-19 | 2019-12-11 | Jiangsu Hengrui Medicine Co | Derivado de benzofurano, método de preparação do mesmo e uso do mesmo em medicina |
EP3407978A4 (en) | 2016-01-29 | 2020-01-15 | Epizyme Inc | COMBINATION THERAPY FOR TREATING CANCER |
US20200377863A1 (en) | 2016-02-10 | 2020-12-03 | Wake Forest University Health Sciences | Model system of liver fibrosis and method of making and using the same |
WO2017157825A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
AU2017248828A1 (en) | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
EP3445365A4 (en) | 2016-04-22 | 2019-10-16 | Dana-Farber Cancer Institute, Inc. | EZH2 INHIBITORS AND USES THEREOF |
CN105777718B (zh) * | 2016-04-27 | 2019-03-19 | 上海应用技术学院 | 潜在ezh2小分子抑制剂及其合成方法 |
US10987353B2 (en) | 2016-05-04 | 2021-04-27 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs |
JP2019521988A (ja) | 2016-06-17 | 2019-08-08 | エピザイム,インコーポレイティド | 癌を処置するためのezh2阻害剤 |
JP2019522049A (ja) * | 2016-06-20 | 2019-08-08 | ノバルティス アーゲー | トリアゾロピリジン化合物及びその使用 |
CN107573336B (zh) * | 2016-07-05 | 2021-01-19 | 四川大学 | 苯并杂环-甲酰胺-吡啶酮衍生物及其制备方法和用途 |
CN107573327B (zh) * | 2016-07-05 | 2020-03-31 | 四川大学 | 吲唑-甲酰胺-吡啶酮衍生物及其制备方法和用途 |
EP3529242A1 (en) | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
CN108698990B (zh) * | 2016-11-11 | 2021-07-30 | 上海海雁医药科技有限公司 | 砜基取代的苯并杂环衍生物、其制法与医药上的用途 |
US20200262813A1 (en) * | 2016-11-11 | 2020-08-20 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 1,5,7-trisubstituted isoquinoline derivatives, preparation thereof, and use thereof in medicines |
WO2018102687A2 (en) | 2016-12-02 | 2018-06-07 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2018135556A1 (ja) | 2017-01-19 | 2018-07-26 | 第一三共株式会社 | Htlv-1関連脊髄症を治療することに用いるための医薬組成物 |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2018231973A1 (en) | 2017-06-13 | 2018-12-20 | Epizyme, Inc. | Inhibitors of ezh2 and methods of use thereof |
KR20200088386A (ko) | 2017-11-14 | 2020-07-22 | 화이자 인코포레이티드 | Ezh2 억제제 병용 요법 |
MX2020007974A (es) | 2018-01-31 | 2020-09-07 | Mirati Therapeutics Inc | Inhibidores de complejo represivo polycomb 2 (prc2). |
CN110229151B (zh) * | 2018-03-06 | 2021-09-10 | 上海海和药物研究开发股份有限公司 | 吲嗪类化合物、其制备方法及用途 |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
WO2020011607A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
EP3831822A4 (en) | 2018-07-27 | 2022-03-23 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | POLY-SUBSTITUTED BENZENE COMPOUND, PROCESS OF MANUFACTURE AND USE THEREOF |
CN113454077A (zh) | 2019-02-22 | 2021-09-28 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
CN109761960B (zh) * | 2019-02-25 | 2021-08-31 | 江苏豪森药业集团有限公司 | 抗耐药抗肿瘤egfr抑制剂的制备方法 |
MX2021013594A (es) | 2019-05-06 | 2021-12-10 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. |
US20220298222A1 (en) | 2019-08-22 | 2022-09-22 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
US12006232B2 (en) | 2020-06-09 | 2024-06-11 | Rapid Water Technology LLC | Water processing apparatus |
CN113307765A (zh) * | 2021-05-24 | 2021-08-27 | 上海泰坦科技股份有限公司 | 吡啶甲胺类化合物及其制备方法 |
WO2023025856A1 (en) | 2021-08-25 | 2023-03-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ezh2 inhibitors for the treatment of aortic valve stenosis |
WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2584713B1 (fr) * | 1985-07-11 | 1988-09-09 | Roussel Uclaf | Nouveaux derives de l'indole carboxamide, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant |
DE10022925A1 (de) * | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
JP4869068B2 (ja) * | 2003-06-19 | 2012-02-01 | スミスクライン ビーチャム コーポレーション | 化合物 |
PE20060748A1 (es) | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
JP5301469B2 (ja) * | 2007-02-26 | 2013-09-25 | メルク カナダ インコーポレイテッド | Ep4受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体 |
PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
AR070398A1 (es) * | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
WO2010036213A1 (en) | 2008-09-26 | 2010-04-01 | Agency For Science, Technology And Research | 3-deazaneplanocin derivatives |
US8637509B2 (en) * | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
JP5864546B2 (ja) * | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | インダゾール |
AU2012223448B2 (en) * | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
-
2011
- 2011-05-05 SG SG2012081501A patent/SG185431A1/en unknown
- 2011-05-05 MA MA35415A patent/MA34284B1/fr unknown
- 2011-05-05 WO PCT/US2011/035336 patent/WO2011140324A1/en active Application Filing
- 2011-05-05 EP EP11778334.0A patent/EP2566327B1/en active Active
- 2011-05-05 UA UAA201213880A patent/UA110112C2/uk unknown
- 2011-05-05 PT PT117783340T patent/PT2566327T/pt unknown
- 2011-05-05 LT LTEP11778334.0T patent/LT2566327T/lt unknown
- 2011-05-05 BR BRBR112012028556-4A patent/BR112012028556A2/pt not_active Application Discontinuation
- 2011-05-05 EA EA201291194A patent/EA023788B1/ru not_active IP Right Cessation
- 2011-05-05 JP JP2013509259A patent/JP5864545B2/ja not_active Expired - Fee Related
- 2011-05-05 RS RS20170410A patent/RS55874B1/sr unknown
- 2011-05-05 MY MYPI2012700879A patent/MY184101A/en unknown
- 2011-05-05 ME MEP-2017-126A patent/ME02757B/me unknown
- 2011-05-05 NZ NZ603454A patent/NZ603454A/en not_active IP Right Cessation
- 2011-05-05 PE PE2012002134A patent/PE20130647A1/es not_active Application Discontinuation
- 2011-05-05 SI SI201131210A patent/SI2566327T1/sl unknown
- 2011-05-05 PL PL11778334T patent/PL2566327T3/pl unknown
- 2011-05-05 HU HUE11778334A patent/HUE034787T2/en unknown
- 2011-05-05 EP EP17162229.3A patent/EP3246027A1/en not_active Withdrawn
- 2011-05-05 AU AU2011248068A patent/AU2011248068B2/en not_active Ceased
- 2011-05-05 CA CA2798622A patent/CA2798622C/en not_active Expired - Fee Related
- 2011-05-05 CN CN201180033600.2A patent/CN102970869B/zh not_active Expired - Fee Related
- 2011-05-05 KR KR1020127031955A patent/KR20130062290A/ko active IP Right Grant
- 2011-05-05 US US13/696,362 patent/US8536179B2/en not_active Expired - Fee Related
- 2011-05-05 DK DK11778334.0T patent/DK2566327T3/en active
- 2011-05-05 ES ES11778334.0T patent/ES2627085T3/es active Active
- 2011-05-05 MX MX2012012966A patent/MX2012012966A/es active IP Right Grant
-
2012
- 2012-11-02 DO DO2012000282A patent/DOP2012000282A/es unknown
- 2012-11-05 IL IL222878A patent/IL222878A/en active IP Right Grant
- 2012-11-06 CR CR20120565A patent/CR20120565A/es unknown
- 2012-11-06 CL CL2012003110A patent/CL2012003110A1/es unknown
- 2012-11-09 ZA ZA2012/08447A patent/ZA201208447B/en unknown
-
2013
- 2013-08-07 US US13/961,044 patent/US8975291B2/en not_active Expired - Fee Related
-
2015
- 2015-01-23 US US14/603,660 patent/US9114141B2/en not_active Expired - Fee Related
- 2015-07-09 US US14/794,911 patent/US9402836B2/en not_active Expired - Fee Related
-
2016
- 2016-06-20 US US15/186,633 patent/US9649307B2/en not_active Expired - Fee Related
-
2017
- 2017-05-05 CY CY20171100488T patent/CY1119006T1/el unknown
- 2017-05-16 HR HRP20170736TT patent/HRP20170736T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201208447B (en) | Indoles | |
EP2646020A4 (en) | INDOLES | |
AP3607A (en) | Substituted imidazopyridazines | |
HK1171452A1 (en) | Substituted pyrrolidine-2-carboxamides -2- | |
EP2547244A4 (en) | PRESS-FRUIT COMBINED WITH A MIXER | |
GB201205984D0 (en) | No details | |
GB201112400D0 (en) | No details | |
GB201015324D0 (en) | Secure association | |
HK1188782A1 (en) | Substituted sodium-1h-pyrazole-5-olate 1h--5- | |
EP2522657A4 (en) | indole derivative | |
EP2572199A4 (en) | COMBINATION | |
EP2571358A4 (en) | COMBINATION | |
IL225393A0 (en) | History of Indole | |
GB201202348D0 (en) | No details | |
GB201016346D0 (en) | Connection means | |
GB201105908D0 (en) | No details | |
EP2603078A4 (en) | COMBINATION | |
EP2575460A4 (en) | COMBINATION | |
EP2654755A4 (en) | COMBINATION | |
EP2654754A4 (en) | COMBINATION | |
GB201118380D0 (en) | No Details | |
GB201202556D0 (en) | No details |